Washington University in St. Louis (WU)
Patients with metastatic breast cancer with bone metastasis as the only site of metastatic disease have lower survival outcomes for CDK4/6inhibitor therapy and immune therapy, we are trying to understand the mechanisms involved in bone met treatment resistance.